QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.104.002832v1 33/6/853    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, P. Articles by Lee, C. A. Search for Related Content PubMed PubMed Citation Articles by Zhao, P. Articles by Lee, C. A.

EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES

Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development La Jolla Laboratories, San Diego, California (P.Z., C.A.L.); and Department of Medicinal Chemistry, School of Pharmacy, University of Washington, Seattle, Washington (K.L.K.)

(Received November 2, 2004; accepted February 24, 2005)

	Abstract

Top Abstract Materials and Methods Results Discussion References

 
Irreversible CYP3A inhibition by drugs constitutes one of the major causes of inhibition-based drug interactions. We evaluated time-dependent inactivation of CYP3A in cryopreserved human hepatocytes for six structurally diverse compounds known to exhibit this property. Inactivation kinetic parameters were also determined using human liver microsomes. Except for diclofenac, which did not cause CYP3A inactivation either in microsomes or in hepatocytes at concentrations up to 100 µM, time-dependent inactivation was observed in hepatocytes for amprenavir, diltiazem, erythromycin, raloxifene, and troleandomycin. The observed inactivation potency in hepatocytes (observed IC₅₀) was compared with the potency predicted using microsomal parameters (predicted IC₅₀). Despite satisfactory prediction for troleandomycin (1.35 and 2.14 µM for the predicted and observed IC₅₀, respectively), over-prediction of inactivation was observed for raloxifene, amprenavir, and erythromycin (observed IC₅₀ values 6.2-, 55-, and 7.8-fold higher, respectively, than the predicted IC₅₀). By contrast, the observed IC₅₀ for diltiazem in hepatocytes was approximately 4-fold lower than the IC₅₀ predicted from microsomal data (under-prediction). After correcting for factors including nonspecific binding and inactivator consumption, prediction was significantly improved for raloxifene (the observed IC₅₀ then became 2-fold higher than the predicted IC₅₀) and for amprenavir to a lesser extent. A specific P-glycoprotein inhibitor, 4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)-N-[2-(3.4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine (CP-100356), modulated the observed CYP3A inactivation potency by erythromycin and troleandomycin. In summary, these studies reveal three important factors that must be considered when microsomal inactivation parameters are used to predict inhibition-based drug interactions in intact cell systems.

Cryopreserved hepatocytes are widely used in drug discovery and development in pharmaceutical industries to predict drug interaction and metabolic clearance for new chemical entities. Hepatocytes have the advantage of maintaining a complete set of drug transporters and phase I/II metabolizing enzymes, not fully represented by HLMs. It is anticipated that factors present in hepatocytes that are absent in microsomal systems may influence the prediction of inhibition-based drug interactions in vivo by directly using microsomal kinetic parameters (k_inact and K_I).

In the present study, we have developed an approach to evaluate the TDI of CYP3A in cryopreserved human hepatocytes. Prediction of the extent of inactivation in hepatocytes was made using kinetic parameters obtained from HLM experiments. The predicted inactivation potency was compared with the values observed in hepatocytes. The reliability of utilizing HLMs to predict TDI in vivo and the feasibility of using hepatocytes to assess TDI will be discussed.

View larger version (21K): [in this window] [in a new window]   FIG. 1. Chemical structures of CYP3A inactivators and CP-100356.

	Materials and Methods

Top Abstract Materials and Methods Results Discussion References

TDI of CYP3A in HLMs. For the main body of this study, 1'-hydroxylation of midazolam was used as the probe reaction for CYP3A in both HLMs and cryopreserved human hepatocytes. TDI in HLMs was performed according to methods described elsewhere (Ito et al., 1998). Briefly, inactivators of varying concentrations were preincubated with HLMs in potassium phosphate buffer (0.1 M, pH 7.4) at 37°C for 5 min before the addition of NADPH. The concentrations of microsomal protein and NADPH were 0.2 mg/ml and 1 mM, respectively. The concentrations for the inactivators were 5 to 80 µM erythromycin, 0.25 to 4 µM diltiazem, 0.75 to 12 µM troleandomycin, 100 µM diclofenac, 0.2 to 10 µM amprenavir, and 1.25 to 10 µM raloxifene. The experiments were performed in triplicate. At different times after the addition of NADPH, 10 µl of the inactivator/HLM mixture (first incubation) were transferred to 90 µl of potassium phosphate buffer containing 100 µM midazolam and 1 mM NADPH (10-fold dilution of inactivator in the incubation with midazolam), which had been preincubated at 37°C for 5 min. The reaction lasted for 1 min and was terminated by the addition of 100 µl of a mixture of acetonitrile/methanol (3:1 v/v) containing alprazolam as internal standard (600 nM). To assess the inactivator consumption during first incubation, samples at time zero and at the last time point after the addition of NADPH were quenched with acetonitrile/methanol (3:1, v/v) containing 600 nM alprazolam.

Microsomal protein binding of the inactivators was determined using equilibrium dialysis as described previously (Obach, 1997; Banker et al., 2003). A multiwell Teflon dialysis apparatus was manufactured at PGRD, and the dialysis membrane (molecular weight cutoff 12,000–14,000) was purchased from Spectrum Medical Industries (Los Angeles, CA). An aliquot (150 µl, n = 3) of a mixture containing HLMs (0.2 mg/ml in 0.1 M potassium phosphate buffer, initial incubation condition for TDI studies) and inactivators (nominal concentrations of 0.5 and 5 µM) was placed on one side of the membrane and blank phosphate buffer was added to the other side. The dialysis chamber was maintained at 37°C for 6 h. Samples were quenched with an equal volume of a mixture of acetonitrile/methanol (3:1) containing alprazolam as internal standard (20 nM). In general, equilibrium was reached between 4 and 6 h for all inactivators (data not shown). Sample extraction and analytical methods for the measurement of inactivators and 1-hydroxymidazolam are described below.

TDI of CYP3A in Cryopreserved Human Hepatocytes. Hepatocyte suspensions were prepared according to the procedures provided by the manufacturer. A pool of five individuals (three male and two female) was used. Briefly, hepatocytes were thawed in thawing medium (25 ml per 5 million hepatocytes) and centrifuged at 50g at room temperature for 5 min. The cell pellet was reconstituted in 30 ml of incubation medium (William's Medium E containing 10 mM HEPES) and centrifuged at 50g at room temperature for 5 min. The resulting cell pellet was reconstituted in fresh incubation medium, and cell viability was determined by the trypan blue method (generally between 78 and 82% viability). Cell suspension was placed in a 37°C incubator supplemented with 5% CO₂ before use.

TDI in Hepatocytes. Hepatocytes were preincubated with and without time-dependent inactivators in a 48-well plate for 1 h in a 37°C incubator under 5% CO₂. The final volume was 250 µl and the final cell concentration was 0.5 x 10⁶ viable cells/ml. The inactivator concentrations were 0.1 to 5 µM amprenavir, 2.5 to 100 µM diclofenac, 0.5 to 4 µM diltiazem, 10 to 80 µM erythromycin, 2.5 to 20 µM raloxifene, and 0.75 to 6 µM troleandomycin. The experiments were performed in triplicate. At the end of preincubation, 200-µl aliquots of the suspension were transferred to 96-well plate microtubes (1.2 ml) and centrifuged at 50g for 5 min at room temperature. One hundred fifty microliters of each supernatant were discarded, and the pellets were resuspended after the addition of 150 µl of fresh medium for washing. The suspension was further centrifuged at 50g for 5 min at room temperature, and 180 µl of each supernatant were discarded. The postwash pellet was resuspended in 100 µl of fresh medium containing midazolam. At this point, the hepatocyte concentration was approximately 1 x 10⁶ cells/ml and midazolam concentration was 100 µM. The suspensions were immediately placed in the incubator (37°C, 5% CO₂) and were incubated for 9 min before the addition of a 2x volume of a mixture of acetonitrile/methanol (3:1 v/v) containing 300 nM alprazolam as internal standard. The use of 100 µM midazolam (to ensure saturation condition) and the choice of 9-min incubation time were confirmed by preliminary kinetic studies.

To assess the effect of competitive inhibition of the inactivators, hepatocytes were preincubated in the absence of inactivator for 1 h and then coincubated with midazolam (100 µM) and each inactivator. The final inactivator concentrations were 2.5 µM amprenavir, 50 µM diclofenac, 1 µM diltiazem, 10 µM erythromycin, 5 µM raloxifene, 2.5 µM troleandomycin, and 2 µM ketoconazole (positive control). The experiments were performed in triplicate. The effect of inactivators on cell viability was evaluated before and after 1-h preincubation by determining glutathione S-transferase activities in the medium of the cell suspension (Habig et al., 1974).

Inactivator Levels during 1-h Preincubation with Hepatocytes. Free inactivator concentration (I_u) was equivalent to total inactivator concentration in hepatocyte medium since no protein was added in this study. Hepatocyte suspensions were centrifuged at 50g for 5 min at 0, 15, 40, and 60 min. The supernatant was quenched with an equal volume of a mixture of acetonitrile/methanol (3:1 v/v) containing alprazolam as internal standard (20 nM final concentration) for the analysis of I_u. In the cases where metabolic consumption and nonspecific binding were significant, a mean time-averaged inhibitor concentration ([) was obtained to represent average I_u during the 1 h of preincubation. Total inactivator levels in the cell suspension before and after the 1-h preincubation were also analyzed.

Effect of Coincubation with Efflux Transport Inhibitor in Hepatocytes. CP-100356, a P-glycoprotein inhibitor, was used to assess the possible involvement of this transporter in the modulation of CYP3A inactivation by the compounds tested in hepatocytes. CP-100356 (0.5 µM) was coincubated with the time-dependent inactivator during the 1-h preincubation of hepatocytes. The cells were washed and the activity of CYP3A was measured as described above.

Liquid Chromatography-Tandem Mass Spectrometry Methods. Samples quenched with organic solvent containing internal standard were vortexed and centrifuged at 1900g for 20 min. The supernatant was analyzed using a Micromass Quattro LC mass spectrometer (Quattro II) equipped with a Waters 2790 high-performance liquid chromatography system (Waters, Milford, MA). Chromatographic separation was performed by a Zorbax C18 column (2 x 50 mm, 5 µm; Agilent Technologies, Palo Alto, CA) coupled with a Keystone Javelin C18 guard column (2 x 20 mm; Western Analytical Products, Inc. Lake Elsinore, CA), at a flow rate of 0.2 to 0.3 ml/min using a linear gradient elution consisting of A, 50 mM ammonium acetate in water; and B, acetonitrile/methanol (89:11, v/v). Table 1 shows the analytical parameters for each analyte described in this study. Alprazolam is the internal standard for all the analytes. The m/z transition for alprazolam is 309205. The retention time of alprazolam varied from 4.9 to 6.4 min due to different high-performance liquid chromatography gradient condition of each analyte (Table 1).

Data Analysis. The percentage of inactivator unbound (% Free) in HLMs was calculated according to eq. 1:

(1)

where [I]_buffer and [I]_HLM were the inactivator concentrations in the buffer side and the microsomal side at equilibrium, respectively.

Kinetic parameters (k_inact and K_I) of CYP3A inactivation in HLMs were obtained by plotting the logarithm of the ratio of the remaining enzyme activity in the presence of inactivator to the activity in the absence of inactivator against the preincubation time. The apparent inactivation rate constant () was determined from the slope of the initial linear phase on the semi logarithmic plots at each inactivator concentration. k_inact and K_I were obtained from the double-reciprocal plots of inactivator concentration [I] versus according to eq. 2 (Kitz and Wilson, 1962).

(2)

TDI of CYP3A in hepatocytes was predicted using kinetic parameters obtained from microsomal incubations according to eq. 3, in which E_i and E₀ were CYP3A activities after 1-h preincubation (t = 60 min) with and without inactivator, respectively.

(3)

View larger version (22K): [in this window] [in a new window]   FIG. 2. TDI of CYP3A in human liver microsomes. Legend shows the inhibitor concentrations in µM.

For inactivators that showed incomplete recovery or significant depletion in hepatocyte incubation, a time-averaged inactivator concentration in the medium ([]) was used to represent the I_u. [] was calculated by trapezoidal integration using monoexponential eq. 4 by WinNonlin software (Version 3.01; Pharsight, Mountain View, CA).

(4)

The observed CYP3A inactivation in hepatocytes was fitted to an inhibitory effect sigmoid E_max model (eq. 5;¹ using WinNonlin software, in which E_max, IC₅₀, and are the maximum enzyme activity, inactivator concentration at which 50% of activity was inhibited, and Hill's coefficient, respectively.

(5)

Using eq. 5, the remaining CYP3A activity was fitted against both nominal inactivator concentrations and the concentrations corrected for nonspecific binding and metabolic consumption (I_u or []) to obtain IC_{50, Nominal} and IC_{50, Corrected}.

Simulations of the inactivation of CYP3A were performed using Microsoft Excel (Microsoft, Redmond, WA). HLM-predicted inactivation was simulated according to eq. 3, and the observed inactivation was simulated according to eq. 5 with either IC_{50, Nominal} or IC_{50, Corrected}.

	Results

Top Abstract Materials and Methods Results Discussion References

 
TDI in HLMs. Figure 2 shows the time-dependent loss of CYP3A activity in HLMs by six compounds reported to exhibit this property. The inactivation rate constants were obtained from the linear portion of the logarithmic ratio E_i/E₀ versus time at each inactivator concentration, as described under Materials and Methods. No apparent CYP3A inactivation was observed for diclofenac at concentrations up to 100 µM. The parameters from this study and literature reports are summarized in Table 2. In general, our findings are in agreement with those reported previously. Amprenavir and raloxifene rapidly inactivated CYP3A under the experimental conditions of this study, exhibiting k_inact values approximately 1 order of magnitude higher than those of diltiazem, erythromycin, and troleandomycin (Table 2).

Inactivator levels during the inactivation incubation (first incubation) were analyzed at time 0 and at the last time point after the addition of NADPH. Table 3 shows that inactivator consumption was not significant for diltiazem, erythromycin, and troleandomycin. In contrast, loss of inactivator was observed for amprenavir and diclofenac at lower concentrations, and for raloxifene at all concentrations. Table 4 shows the inactivator microsomal free fraction at nominal 0.5 and 5 µM concentrations. The unbound fraction of raloxifene was 15 and 23% at 0.5 and 5 µM, respectively. Diclofenac also showed 47% microsomal binding at 0.5 µM. No significant microsomal protein binding was observed for the other compounds. Therefore, the apparent K_I for raloxifene and amprenavir (Table 2) are overestimates due to potential microsomal binding and/or inactivator consumption (Tables 3 and 4).

TDI of CYP3A in Cryopreserved Human Hepatocytes. The use of cryopreserved human hepatocytes for the study of TDI was validated as described under Materials and Methods. Cell viabilities were not different before and after 1-h preincubation in the absence or presence of the highest concentrations of inactivators (data not shown). CYP3A activities before and after 1-h preincubation were 56.3 ± 3.4 and 56.6 ± 3.0 pmol of 1-hydroxymidazolam per min per 10⁶ cells, respectively (n = 3 separate incubations). As shown in Fig. 3 (open diamonds), amprenavir, diltiazem, erythromycin, raloxifene, and troleandomycin showed concentration-dependent CYP3A inactivation in hepatocytes after 1-h preincubation. Diclofenac had minimal effect on CYP3A activity at concentrations up to 100 µM (data not shown).

View larger version (20K): [in this window] [in a new window]   FIG. 3. Effect of 1-h preincubation of inactivators on CYP3A activities in cryopreserved human hepatocytes. Open square, HLM-predicted inactivator concentration that caused the same inactivation observed in hepatocytes. Open diamond, observed CYP3A activity at nominal concentration of the inactivator (n = 3, CV = 2–18%). Closed diamond, observed CYP3A activity at corrected concentration using Iu (diltiazem) or [] (amprenavir and raloxifene). Solid lines, simulated inactivation using eq. 4, Emax, IC50, and . Broken lines, predicted inactivation using HLM parameters according to eq. 2 (Table 2).

Calculation of I_u in Hepatocyte Experiments. Table 6 summarizes the inactivator levels measured in the hepatocyte incubations. Inactivator levels in the medium are equal to I_u since no protein was added in the medium. Active uptake and/or nonspecific binding can be evaluated by assessing the recovery of the inactivators (I_u as a percentage of total concentration) at time 0. The recovery of the inactivator in the medium at time 0 was complete (near unity) for erythromycin and troleandomycin. However, the recovery ratios for raloxifene, amprenavir, diltiazem, and diclofenac were approximately 0.1, 0.4, 0.75, and 0.8, respectively. Inactivator consumption can be evaluated by measuring the percentage remaining of both I_u and total inactivator concentration after 1-h preincubation. Table 6 shows significant inactivator consumption for amprenavir (at lower concentrations), raloxifene, and diclofenac. The time courses of the I_u change for amprenavir and raloxifene are shown in Fig. 4. Taken together, the data demonstrated that it was not appropriate to use I_u at any single time point to represent the effective inactivator concentration for amprenavir and raloxifene. Instead, a time-averaged free inactivator concentration ([]) (eq. 4) was used. Therefore, for inactivators displaying low recovery in hepatocyte incubation medium, the nominal concentrations were replaced by I_u (for diltiazem) and [] for amprenavir and raloxifene (Fig. 4) for further evaluation (Table 7; Fig. 3).

View larger version (12K): [in this window] [in a new window]   FIG. 4. Inactivator concentrations of raloxifene (left panel) and amprenavir (right panel) in hepatocyte incubation medium during 1-h preincubation. Legends show the nominal concentrations of each inactivator.

Prediction of TDI of CYP3A in Cryopreserved Hepatocytes using Microsomal Parameters. Comparison between the observed inactivation and HLM-predicted inactivation in hepatocytes was conducted. The practice was only to provide a descriptive relationship for the limited number of inactivators used in this study and was not meant to generate a quantitative correlation between the two systems. Diclofenac was excluded because of the absence of TDI under the conditions used in this study. Table 7 summarizes the observed inactivation (IC_{50, Nominal} and IC_{50, Corrected}) and HLM-predicted inactivation (IC_{50, Predicted}). Under-prediction was defined when IC_{50, Predicted} was higher than IC_{50, Nominal} in hepatocytes, whereas over-prediction was defined when IC_{50, Predicted} was lower than IC_{50, Nominal}. Microsomal parameters of diltiazem apparently under-predicted the inactivation by approximately 4-fold (IC_{50, Nominal} and IC_{50, Predicted} of 3.22 and 12.32 µM, respectively). Correction of the observed inactivation using I_u in hepatocytes tends to magnify the under-prediction (IC_{50, Corrected} became 2.41 µM). On the other hand, over-prediction was observed for the remaining four inactivators. The IC_{50, Nominal} was 55-, 6.2-, and 7.8-fold higher than IC_{50, Predicted} for amprenavir, erythromycin, and raloxifene, respectively. Predicted inactivation by troleandomycin appears to be the most accurate (IC_{50, Nominal} and IC_{50, Predicted} of 2.14 and 1.35 µM, respectively). Correction of the observed inactivation using [] markedly narrowed the difference between the observed and predicted IC₅₀ values for raloxifene and amprenavir. The observed IC_{50, Corrected} for raloxifene was 1.01 µM as compared with the IC_{50, Predicted} of 0.62 µM. The IC_{50, Corrected} for amprenavir became 0.36 µM (versus IC_{50, Nominal} = 1.09 µM) as compared with the IC_{50, Predicted} of 0.02 µM. I_u or [] correction was not made for troleandomycin and erythromycin due to their relative complete recoveries and the absence of metabolic consumption (Table 7). The differences between the observed inactivation and the predicted inactivation can also be visualized by the simulated inactivation curves in Fig. 3. Observed inactivation was simulated using parameters generated according to eq. 5 using both IC_{50, Nominal} and IC_{50, Corrected}, whereas the predicted inactivation was simulated using HLM parameters (eq. 3, t = 60 min) for each compound tested.

Effect of Efflux Transporter on TDI of CYP3A in Hepatocytes. To assess the effect of P-glycoprotein on the inactivation potency of the compounds tested, hepatocytes were coincubated with 0.5 µM CP-100356 and each inactivator during the 1-h preincubation. The concentrations chosen for each inactivator (0.5, 2, 20, 5, and 1.5 µM for amprenavir, diltiazem, erythromycin, raloxifene, and troleandomycin, respectively) are close to the observed respective IC_{50, Nominal} values in this study (Fig. 3; Table 7). The concentration of CP-100356 (0.5 µM) was approximately 20-fold lower than its IC₅₀ for CYP3A and about 5-fold higher than the IC₅₀ for P-glycoprotein as reported by Wandel et al. (1999). CYP3A activity was not affected when 0.5 µM CP-100356 was present in the 1-h preincubation (data not shown). Figure 5 shows the effect of coincubation of CP-100356 on the inactivation potency for each compound tested. CP-100356 significantly enhanced CYP3A inactivation potency of the macrolides, troleandomycin and erythromycin (p < 0.01 and p < 0.05, respectively). CP-100356 did not significantly alter the inactivation potencies of raloxifene, diltiazem, and amprenavir.

View larger version (15K): [in this window] [in a new window]   FIG. 5. Effect of P-glycoprotein inhibitor CP-100356 (0.5 µM) on the CYP3A inactivation potency by time-dependent inactivators in cryopreserved hepatocytes (mean ± S.D., n = 4 incubations). Inactivator concentrations: amprenavir, 0.5 µM; diltiazem, 2 µM; erythromycin, 20 µM; raloxifene, 5 µM; troleandomycin, 1.5 µM. *, p < 0.05; **, p < 0.01.

	Discussion

Top Abstract Materials and Methods Results Discussion References

Time-dependent cytochrome P450 inactivation results from the formation of reactive metabolites or intermediates, which bind tightly or irreversibly to the heme or apoprotein, leading to a catalytically inactive protein. Consequently, the concentration of active enzyme is controlled by the rate of enzyme inactivation as well as endogenous rates of de novo synthesis and degradation (Lin and Lu, 1998). The generally accepted approach for the prediction of the magnitude of TDI in vivo has been to apply microsomal kinetic parameters and the projected [I] (eq. 2), together with estimates of the endogenous degradation rate constant of the "victim" enzyme (Mayhew et al., 2000). Although successful for some compounds (Kanamitsu et al., 2000; Mayhew et al., 2000; Ito et al., 2003), direct use of microsomal parameters may fail to predict in vivo drug-interactions for marketed drugs known to have TDI properties (Liras, 2003).

In this report, we evaluated the TDI of CYP3A in two widely used systems, HLMs and cryopreserved hepatocytes, for six compounds from different therapeutic classes. Pooled liver preparations were used to take into account the interindividual variability associated with the CYP3A family. Raloxifene, a selective estrogen receptor modulator, was shown to inactivate CYP3A4 via a reactive intermediate from the active site, which can be attenuated by glutathione (Chen et al., 2002). Macrolide antibiotics, erythromycin and troleandomycin, are believed to form complexes with heme through a nitroso intermediate initiated by CYP3A through N-dealkylation (Periti et al., 1992). Similarly, TDI caused by the vasodilator diltiazem appears to be due to further metabolism of its N-desmethyl-diltiazem metabolite (Jones et al., 1999; Mayhew et al., 2000). The HIV protease inhibitor amprenavir was recently shown to inhibit CYP3A by binding to the heme (Ernest et al., 2003). The nonsteroidal anti-inflammatory agent diclofenac was reported to be a time-dependent inactivator of CYP3A with a rather high K_I of 1.6 mM (Masubuchi et al., 2002).

We did not observe TDI by diclofenac in either HLMs or hepatocytes at concentrations up to 100 µM. Further investigation at higher concentrations was not conducted because 100 µM is already much higher than free diclofenac exposure observed in humans. Indeed, diclofenac was not likely to cause clinically relevant CYP3A inhibition, given its high microsomal K_I and high plasma protein binding (Masubuchi et al., 2002). Thus, diclofenac was excluded from the HLM-hepatocyte prediction exercise. The remaining five inactivators demonstrated a concentration-dependent and time-dependent CYP3A inactivation in hepatocytes after 1-h preincubation (Table 5).

In general, HLM-based prediction overestimates the inactivation potency observed in hepatocytes for troleandomycin, erythromycin, raloxifene, and amprenavir by approximately 2- to 60-fold (IC_{50, Predicted} lower than IC_{50, Nominal}, Table 7). The discrepancy may be due to metabolic stability, nonspecific binding, active transport, or the combination of these factors. The depletion of the unbound inhibitor concentration available to the enzyme may introduce serious error into a quantitative prediction of an in vivo drug-drug interaction (Gibbs et al., 1999a; Xu et al., 2003). Among the inactivators tested, amprenavir and raloxifene had significantly low recoveries in the hepatocyte medium after the compounds were spiked into the cell suspension (approximately 10–40% recoveries, Table 6), suggesting concentrative uptake of these two compounds into the hepatocytes, mediated either by uptake transport or high lipophilicity. Indeed, the calculated logD_7.4 values for amprenavir and raloxifene were 4.2 and 5.5, respectively (ACD Labs, Toronto, ON, Canada), which are the highest among the compounds tested in this study. The significant microsomal binding for raloxifene may imply strong nonspecific binding of this compound to cellular constituents in hepatocyte incubations (Tables 4 and 6). Metabolic consumption during the 1-h preincubation in hepatocytes further decreased the availability of inactivator to the enzyme. The major biotransformation pathway for raloxifene is glucuronidation (Kemp et al., 2002). Effects of phase II enzyme are often not represented in HLM experiments. The discrepancy between I_u and nominal concentration for amprenavir may be partly attributed to the metabolic consumption by CYP3A (Treluyer et al., 2003). Correction using [] improved the prediction markedly for raloxifene and to a lesser extent for amprenavir. One should also note that the apparent K_I values are likely overestimates for raloxifene and amprenavir, given that microsomal binding and/or HLM metabolic consumption (Tables 3 and 4) would theoretically widen the gap between the predicted IC₅₀ and the observed IC₅₀.

The major assumption of these predictions is that entry of inactivator into the cell is not rate-limiting and is mediated by diffusion only (free drug hypothesis). However, if the inactivator is a substrate of active transporter(s), I_u in the medium will no longer represent the intracellular inactivator concentration. Lam and Benet (2004) have demonstrated that the metabolism of digoxin (a substrate of both uptake and efflux transporters) in freshly isolated rat hepatocyte suspension can be modulated by inhibitors of both uptake and efflux transporters.

In this study, we chose CP-100356, a P-glycoprotein inhibitor (Wandel et al., 1999), to address the potential influencing factors associated with active transporters. If P-glycoprotein were functionally active in cryopreserved hepatocytes by reducing intracellular inactivator levels, or by efficiently removing obligatory metabolites of the pathway, one would observe decreased inactivation. To date, little is known about the expression, function, and orientation of P-glycoprotein after cryopreservation. In intact liver, hepatocytes are polarized, with transporters preferentially expressed on either the basolateral membrane or the bile canalicular membrane. The disruption of polarity upon collagenase isolation of hepatocytes may lead to the loss of P-glycoprotein. Roelofsen et al. (1995) have demonstrated the endocytosis of canalicular multispecific organic anion transporter after isolation of rat hepatocytes, which was confirmed by the disappearance of transport activity from the cell surface and the appearance of intracellular vesicles that accumulate the substrate. Assuming P-glycoprotein undergoes similar changes, one would expect the decreased availability of a P-glycoprotein substrate to cytoplasmic components (such as CYP3A) due to efflux by the remaining cell membrane P-glycoprotein activity and/or accumulation into the intracellular vesicles by P-glycoprotein. We demonstrated that coincubation of 0.5 µM CP-100356 (a concentration that did not inhibit CYP3A) significantly increased the CYP3A inactivation potency by troleandomycin and erythromycin (Fig. 5). Interestingly, amprenavir has been shown to be a P-glycoprotein substrate (Polli et al., 1999; Choo et al., 2000; Huang et al., 2001); however, CP-100356 did not alter its inactivation potency (Fig. 5). The strong concentrative effect observed for amprenavir may have masked the P-glycoprotein-mediated efflux. Like many P-glycoprotein inhibitors, the selectivity of CP-100356 toward other transporters is not known, and the modulation of the CYP3A inactivation potency for macrolide antibiotics may have arisen from the inhibition of basolateral efflux transporter(s), which does not recognize amprenavir as a substrate. Our findings of effects of CP-100356 on macrolide-induced inactivation suggested that P-glycoprotein (or other efflux proteins that can be inhibited by CP-100356) may have survived and maintained its efflux functionality during the hepatocyte cryopreservation and resuspension. It has to be noted that cryopreserved hepatocytes are widely used to predict drug interaction and in vivo metabolic clearance of a new chemical entity. Thus, for compounds that are substrates for active transporters, care should be taken when interpreting data collected from cryopreserved hepatocytes to predict in vivo outcome. It is also recognized that other transporters (both uptake and efflux) that survived cryopreservation and resuspension can also contribute to the discrepancy between HLMs and hepatocytes observed in this study. Further investigation of the mechanism through which efflux transporters alter the inactivation potency of macrolide antibiotics will be conducted.

The apparent discrepancy of the 4-fold difference between IC_{50, Nominal} and IC_{50, Predicted} for diltiazem (Table 7) is difficult to address. The low microsomal k_inact (0.012 min^-1) value of diltiazem is very close to the predicted value that would cause 50% inhibition (0.0115 min^-1 at 60 min; eq. 3). Mathematically, predicting inactivator concentration that causes more than 50% inactivation in hepatocytes results in a negative value (eq. 3). It is also noted that the IC_{50, Predicted} is greater than microsomal K_I (Table 7), implying that the prediction of 50% inactivation in hepatocytes is operated at = k_inact (eq. 2). Together, one would expect a large degree of uncertainty of IC_{50, Predicted} under the conditions set up in this report. For compounds with low k_inact such as diltiazem, it appears to be very difficult to detect the existence of TDI from microsomal experiments (Fig. 3), whereas individuals on diltiazem (60 mg, three times a day for 3 days) had a 2-fold increase of triazolam exposure (Kosuge et al., 1997). Our observation of CYP3A inactivation in hepatocytes for compounds with low k_inact such as diltiazem shows the potential advantage of using hepatocytes as a means to evaluate the projected in vivo potency of a time-dependent inactivator obtained from microsomal experiments.

In conclusion, when potential factors such as metabolic consumption, nonspecific binding, and active transport are considered, cryopreserved hepatocytes can augment the use of HLMs as a tool to evaluate a compound's potential to cause TDI in vivo.

	Acknowledgments

 
We thank David Neul for hepatocyte preparations. The valuable suggestions and advice from Yun Xu, Dr. Rene H. Levy (University of Washington) regarding inhibitor depletion, and Dr. Alfin Vaz (Pfizer Groton) regarding assessment of TDI in hepatocytes were sincerely appreciated. We also thank Drs. Ellen Y. Wu, James L. Ferrero, William Pool, and Wei-Zhu Zhong for carefully reviewing the manuscript and valuable comments.

	Footnotes

 
This work was partially supported by National Institutes of Health Grant GM32165.

Article, publication date, and citation information can be found at http://dmd.aspetjournals.org.

doi:10.1124/dmd.104.002832.

ABBREVIATIONS: TDI, time-dependent inactivation; HLM, human liver microsome; PGRD, Pfizer Global R&D; CP100356, 4-(6,7-dimethoxy-3,4-dihydroisoquinoline-2(1H)-yl)-N-[2-(3,4-dimethoxyphenyl)ethyl]-6,7-dimethoxyquinazolin-2-amine; IC_{50, Nominal}, the nominal concentration of inactivator to cause 50% inactivation observed in hepatocytes; IC_{50, Corrected}, IC₅₀ corrected for nonspecific binding and time-dependent loss due to metabolism in hepatocytes; IC_{50, Predicted}, predicted inactivator concentration in hepatocytes that produced 50% inactivation of CYP3A activity using microsomal parameters; I_u, free inactivator concentration in hepatocyte incubation medium; [] time-averaged inactivator concentration in the hepatocyte incubation medium; K_I, apparent inactivation constant; k_inact, maximum inactivation rate constant; , apparent inactivation rate constant.

¹ We have chosen the inhibitory E_max model to estimate the observed inactivation IC₅₀ based on a limited number of observations (four for each inactivator). However, one should note that this is not an appropriate model to quantitatively assess the time-dependent event in hepatoctye incubations.

Address correspondence to: Dr. Ping Zhao, Pharmacokinetics, Dynamics and Metabolism, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Dr., San Diego, CA 92121. E-mail: ping.zhao2{at}pfizer.com

	References

Top Abstract Materials and Methods Results Discussion References

 


Banker MJ, Clark TH, and Williams JA (2003) Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein binding. J Pharm Sci 92: 967-974.[CrossRef][Medline]

Chen Q, Ngui JS, Doss GA, Wang RW, Cai X, DiNinno FP, Blizzard TA, Hammond ML, Stearns RA, Evans DC, et al. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem Res Toxicol 15: 907-914.[CrossRef][Medline]

Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, and Kim RB (2000) Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28: 655-660.[Abstract/Free Full Text]

Dai R, Wei X, Luo G, Sinz M, and Marathe P (2003) Metabolism-dependent P450 3A4 inactivation with multiple substrates. Abstract from 12^th North American ISSX Meeting. Providence, RI. Drug Metab Rev 35 (Suppl 2): 341.

Ernest CS II, Hall SD, and Jones DR (2003) Mechanism-based inactivation of cytochrome P450 3A (CYP3A) by HIV protease inhibitors (PI's). Abstract from 12^th North American ISSX Meeting. Providence, RI. Drug Metab Rev 35 (Suppl 2): 339.

Gibbs MA, Kunze KL, Howald WN, and Thummel KE (1999a) Effect of inhibitor depletion on inhibitory potency: tight binding inhibition of CYP3A by clotrimazole. Drug Metab Dispos 27: 596-569.[Abstract/Free Full Text]

Gibbs MA, Thummel KE, Shen DD, and Kunze KL (1999b) Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab Dispos 27: 180-187.[Abstract/Free Full Text]

Habig WH, Pabst MJ, and Jakoby WB (1974) Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem 240: 7130-7139.

Huang L, Wring SA, Woolley JL, Brouwer KR, Serabjit-Singh C, and Polli JW (2001) Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29: 754-760.[Abstract/Free Full Text]

Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, and Sugiyama Y (1998) Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 50: 387-412.[Abstract/Free Full Text]

Ito K, Ogihara K, Kanamitsu S, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31: 945-954.[Abstract/Free Full Text]

Jones DR, Gorski JC, Hamman MA, Mayhew BS, Rider S, and Hall SD (1999) Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J Pharmacol Exp Ther 290: 1116-1125.[Abstract/Free Full Text]

Kanamitsu S, Ito K, Green CE, Tyson CA, Shimada N, and Sugiyama Y (2000) Prediction of in vivo interaction between triazolam and erythromycin based on in vitro studies using human liver microsomes and recombinant human CYP3A4. Pharm Res (NY) 17: 419-426.

Kemp DC, Fan PW, and Stevens JC (2002) Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Drug Metab Dispos 30: 694-700.[Abstract/Free Full Text]

Kitz R and Wilson IB (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J Biol Chem 237: 3245-3249.[Free Full Text]

Kosuge K, Nishimoto M, Kimura M, Umemura K, Nakashima M, and Ohashi K (1997) Enhanced effect of triazolam with diltiazem. Br J Clin Pharmacol 43: 367-372.[CrossRef][Medline]

Lam JL and Benet LZ (2004) Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metab Dispos 32: 1311-1316.[Abstract/Free Full Text]

Lin JH and Lu AY (1998) Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 35: 361-390.[CrossRef][Medline]

Liras J (2003) Evaluation of an in vitro tool to predict clinical drug interactions from inactivation of cytochrome P450 3A4. Poster presentation. 6^th International Conference on Drug-Drug Interactions, San Diego, CA, June 23-25, 2003. Institute for Scientific Exchange, Inc., Baltimore, MD.

Masubuchi Y, Ose A, and Horie T (2002) Diclofenac-induced inactivation of CYP3A4 and its stimulation by quinidine. Drug Metab Dispos 30: 1143-1148.[Abstract/Free Full Text]

Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28: 1031-1037.[Abstract/Free Full Text]

Obach RS (1997) Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Metab Dispos 25: 1359-1369.[Abstract/Free Full Text]

Periti P, Mazzei T, Mini E, and Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23: 106-131.[Medline]

Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, and Woolley JL (1999) Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res (NY) 16: 1206-1212.

Roelofsen H, Bakker CT, Schoemaker B, Heijn M, Jansen PL, and Elferink RP (1995) Redistribution of canalicular organic anion transport activity in isolated and cultured rat hepatocytes. Hepatology 21: 1649-1657.[CrossRef][Medline]

Treluyer JM, Bowers G, Cazali N, Sonnier M, Rey E, Pons G, and Cresteil T (2003) Oxidative metabolism of amprenavir in the human liver. Effect of the CYP3A maturation. Drug Metab Dispos 31: 275-281.[Abstract/Free Full Text]

Wandel C, Kim RB, Kajiji S, Guengerich FP, Wilkinson GR, and Wood AJJ (1999) P-Glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies. Cancer Res 59: 3944-3948.[Abstract/Free Full Text]

Xu Y, Black C, Kunze K, and Levy R (2003) Determination of unbound Ki values of fluvoxamine toward CYP2C9 activity in human liver microsomes (HLM) and fresh human hepatocytes. Abstract from 12^th North American ISSX Meeting. Providence, RI. Drug Metab Rev 35 (Suppl 2): 353.

This article has been cited by other articles:

				K. Grime, P. J. H. Webborn, and R. J. Riley Functional Consequences of Active Hepatic Uptake on Cytochrome P450 Inhibition in Rat and Human Hepatocytes Drug Metab. Dispos., August 1, 2008; 36(8): 1670 - 1678. [Abstract] [Full Text] [PDF]

				A. Watanabe, K. Nakamura, N. Okudaira, O. Okazaki, and K.-i. Sudo Risk Assessment for Drug-Drug Interaction Caused by Metabolism-Based Inhibition of CYP3A Using Automated in Vitro Assay Systems and Its Application in the Early Drug Discovery Process Drug Metab. Dispos., July 1, 2007; 35(7): 1232 - 1238. [Abstract] [Full Text] [PDF]

				M. G. Soars, K. Grime, J. L. Sproston, P. J. H. Webborn, and R. J. Riley Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo Drug Metab. Dispos., June 1, 2007; 35(6): 859 - 865. [Abstract] [Full Text] [PDF]

				P. Zhao, C. A. Lee, and K. L. Kunze Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A Drug Metab. Dispos., May 1, 2007; 35(5): 704 - 712. [Abstract] [Full Text] [PDF]

				D. F. McGinnity, A. J. Berry, J. R. Kenny, K. Grime, and R. J. Riley EVALUATION OF TIME-DEPENDENT CYTOCHROME P450 INHIBITION USING CULTURED HUMAN HEPATOCYTES Drug Metab. Dispos., August 1, 2006; 34(8): 1291 - 1300. [Abstract] [Full Text] [PDF]

				D. F. McGinnity, J. Tucker, S. Trigg, and R. J. Riley PREDICTION OF CYP2C9-MEDIATED DRUG-DRUG INTERACTIONS: A COMPARISON USING DATA FROM RECOMBINANT ENZYMES AND HUMAN HEPATOCYTES Drug Metab. Dispos., November 1, 2005; 33(11): 1700 - 1707. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: dmd.104.002832v1 33/6/853    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhao, P. Articles by Lee, C. A. Search for Related Content PubMed PubMed Citation Articles by Zhao, P. Articles by Lee, C. A.